CA2935683A1 - Therapeutic inhibitory compounds - Google Patents
Therapeutic inhibitory compounds Download PDFInfo
- Publication number
- CA2935683A1 CA2935683A1 CA2935683A CA2935683A CA2935683A1 CA 2935683 A1 CA2935683 A1 CA 2935683A1 CA 2935683 A CA2935683 A CA 2935683A CA 2935683 A CA2935683 A CA 2935683A CA 2935683 A1 CA2935683 A1 CA 2935683A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- alkyl
- chloro
- oxopyridin
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361921995P | 2013-12-30 | 2013-12-30 | |
| US61/921,995 | 2013-12-30 | ||
| US201462025203P | 2014-07-16 | 2014-07-16 | |
| US62/025,203 | 2014-07-16 | ||
| PCT/US2014/072851 WO2015103317A1 (en) | 2013-12-30 | 2014-12-30 | Therapeutic inhibitory compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2935683A1 true CA2935683A1 (en) | 2015-07-09 |
Family
ID=53493998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2935683A Abandoned CA2935683A1 (en) | 2013-12-30 | 2014-12-30 | Therapeutic inhibitory compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10266515B2 (enExample) |
| EP (1) | EP3089746A4 (enExample) |
| JP (1) | JP6759100B2 (enExample) |
| KR (1) | KR20160106627A (enExample) |
| CN (1) | CN106061480B (enExample) |
| AU (2) | AU2014373735B2 (enExample) |
| BR (1) | BR112016015449A8 (enExample) |
| CA (1) | CA2935683A1 (enExample) |
| EA (1) | EA032713B1 (enExample) |
| MX (1) | MX2016008688A (enExample) |
| WO (1) | WO2015103317A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| HUE14755117T2 (hu) | 2013-08-14 | 2018-12-28 | Kalvista Pharmaceuticals Ltd | Plazma-kallikrein inhibitorok |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| US9611252B2 (en) * | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| US10266515B2 (en) | 2013-12-30 | 2019-04-23 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| PL3925607T5 (pl) | 2014-04-15 | 2026-06-01 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| KR102286305B1 (ko) * | 2014-07-16 | 2021-08-09 | 라이프에스씨아이 파마슈티컬스, 인크. | 치료적 억제 화합물 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| US12282014B2 (en) | 2015-11-19 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers |
| WO2017122754A1 (ja) | 2016-01-12 | 2017-07-20 | 日本ケミファ株式会社 | 電位依存性ｔ型カルシウムチャネル阻害剤 |
| ME03794B (me) | 2016-05-31 | 2021-04-20 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| CN107033015B (zh) * | 2017-06-02 | 2019-04-30 | 南京欧信医药技术有限公司 | 一种药物中间体的合成方法 |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| PL3716952T3 (pl) | 2017-11-29 | 2022-05-02 | Kalvista Pharmaceuticals Limited | Postacie dawkowania zawierające inhibitor kalikreiny osoczowej |
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| EP3758702A4 (en) * | 2018-02-28 | 2021-11-10 | Attune Pharmaceuticals, Inc. | TREATMENT OF HEREDITARY ANGIOEDEMA |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| CN112135825A (zh) * | 2018-03-13 | 2020-12-25 | 夏尔人类遗传性治疗公司 | 血浆激肽释放酶抑制剂及其用途 |
| WO2019231935A1 (en) | 2018-05-29 | 2019-12-05 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| US12509453B2 (en) | 2019-01-29 | 2025-12-30 | Foghorn Therapeutics Inc. | BRM/BRG1 inhibitors and uses thereof |
| US12384776B2 (en) | 2019-01-29 | 2025-08-12 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN110256342B (zh) * | 2019-07-16 | 2022-06-07 | 河南省科学院化学研究所有限公司 | 一种2-氰基喹啉衍生物的合成方法 |
| WO2021028645A1 (en) * | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021055589A1 (en) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Heteroaryl plasma kallikrein inhibitors |
| CN114728962B (zh) | 2019-09-18 | 2025-09-19 | 武田药品工业有限公司 | 血浆激肽释放酶抑制剂及其用途 |
| BR112022010895A2 (pt) | 2019-12-04 | 2022-09-06 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan |
| AU2020395306B2 (en) | 2019-12-04 | 2025-04-24 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| JP7699389B2 (ja) | 2019-12-04 | 2025-06-27 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| PH12022551379A1 (en) | 2019-12-06 | 2023-05-03 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
| WO2021155264A1 (en) * | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2021155262A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| US12606553B2 (en) | 2021-03-09 | 2026-04-21 | Foghorn Therapeutics Inc. | Crystalline forms, compositions containing same, and methods of their use |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| US12319655B2 (en) | 2021-12-09 | 2025-06-03 | Deciphera Pharmaceuticals, Llc | RAF kinase inhibitors and methods of use thereof |
| WO2024059186A1 (en) * | 2022-09-15 | 2024-03-21 | Takeda Pharmaceutical Company Limited | N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema |
| CN119604497A (zh) * | 2023-06-30 | 2025-03-11 | 远森制药（杭州）有限公司 | 杂芳族甲酰胺类化合物及其在医药上的应用 |
| WO2025160190A1 (en) * | 2024-01-23 | 2025-07-31 | Retune Pharma Inc. | Therapeutic inhibitory compounds |
| WO2025247982A1 (en) * | 2024-05-29 | 2025-12-04 | Grünenthal GmbH | Piperazines which act as sstr4 modulators |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW212792B (enExample) * | 1991-09-13 | 1993-09-11 | Shell Internat Res Schappej B V | |
| IL108459A0 (en) * | 1993-02-05 | 1994-04-12 | Opjohn Company | 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| TW575562B (en) * | 1998-02-19 | 2004-02-11 | Agrevo Uk Ltd | Fungicides |
| CA2390923A1 (en) * | 1999-11-10 | 2001-05-31 | Takeda Chemical Industries, Ltd. | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| MXPA04009541A (es) * | 2002-03-29 | 2005-01-25 | Chiron Corp | Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf. |
| JP2006519258A (ja) * | 2003-02-28 | 2006-08-24 | エンサイシブ・ファーマシューティカルズ・インコーポレイテッド | ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ｉｉ受容体拮抗薬 |
| GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
| US20090227612A1 (en) * | 2005-12-22 | 2009-09-10 | Boonsaeng Park | Aminopyrimidine Derivatives Inhibiting Protein Kinase Activity, Method For The Preparation Thereof And Pharmaceutical Composition Containing Same |
| US20070254894A1 (en) * | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| WO2007098352A2 (en) | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| CA2672167C (en) * | 2006-12-14 | 2016-01-26 | Bayer Schering Pharma Aktiengesellschaft | Dihydropyridine derivatives useful as protein kinase inhibitors |
| JP2010518146A (ja) * | 2007-02-16 | 2010-05-27 | グラクソ グループ リミテッド | ベンゾフラン化合物 |
| EP2002834A1 (de) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
| WO2009083553A1 (en) * | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
| CA2718727A1 (en) | 2008-03-25 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US20090270407A1 (en) | 2008-04-25 | 2009-10-29 | E. I. Du Pont De Nemours And Company | Fungicidal isoxazolidines |
| US20110124626A1 (en) | 2008-07-18 | 2011-05-26 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives and their use as histamine h3 antagonists |
| CA2741666C (en) | 2008-10-31 | 2017-04-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| US8980892B2 (en) * | 2009-03-26 | 2015-03-17 | Syngenta Crop Protection Llc | Insecticidal compounds |
| GB201004739D0 (en) * | 2010-03-22 | 2010-05-05 | Prosidion Ltd | Receptor modulators |
| US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| RU2632900C2 (ru) * | 2010-11-19 | 2017-10-11 | Лиганд Фармасьютикалс Инкорпорейтед | Гетероциклические амины и их применение |
| GB201021103D0 (en) * | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| CN102904742B (zh) | 2011-07-29 | 2015-10-07 | 华为终端有限公司 | 对可执行节点的操作方法及系统 |
| WO2013040436A2 (en) * | 2011-09-16 | 2013-03-21 | The Regents Of The University Of Michgian | Esx-mediated transcription modulators and related methods |
| US9206128B2 (en) * | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US20140378474A1 (en) | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| US20140350034A1 (en) | 2012-01-27 | 2014-11-27 | Novartis Ag | Aminopyridine derivatives as plasma kallikrein inhibitors |
| SG11201504475QA (en) | 2012-12-07 | 2015-07-30 | Hoffmann La Roche | Pyridine-2-amides useful as cb2 agonists |
| RU2712621C2 (ru) | 2013-05-23 | 2020-01-30 | Калвиста Фармасьютикалз Лимитед | Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы |
| HUE14755117T2 (hu) | 2013-08-14 | 2018-12-28 | Kalvista Pharmaceuticals Ltd | Plazma-kallikrein inhibitorok |
| US10266515B2 (en) * | 2013-12-30 | 2019-04-23 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| KR102286305B1 (ko) * | 2014-07-16 | 2021-08-09 | 라이프에스씨아이 파마슈티컬스, 인크. | 치료적 억제 화합물 |
| GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
-
2014
- 2014-12-30 US US14/800,631 patent/US10266515B2/en not_active Expired - Fee Related
- 2014-12-30 CA CA2935683A patent/CA2935683A1/en not_active Abandoned
- 2014-12-30 JP JP2016544593A patent/JP6759100B2/ja not_active Expired - Fee Related
- 2014-12-30 KR KR1020167020567A patent/KR20160106627A/ko not_active Ceased
- 2014-12-30 WO PCT/US2014/072851 patent/WO2015103317A1/en not_active Ceased
- 2014-12-30 EP EP14877414.4A patent/EP3089746A4/en not_active Withdrawn
- 2014-12-30 AU AU2014373735A patent/AU2014373735B2/en not_active Ceased
- 2014-12-30 MX MX2016008688A patent/MX2016008688A/es unknown
- 2014-12-30 EA EA201691354A patent/EA032713B1/ru unknown
- 2014-12-30 CN CN201480076616.5A patent/CN106061480B/zh not_active Expired - Fee Related
- 2014-12-30 BR BR112016015449A patent/BR112016015449A8/pt active Search and Examination
-
2019
- 2019-04-02 US US16/373,391 patent/US20200031799A1/en not_active Abandoned
-
2020
- 2020-03-03 AU AU2020201550A patent/AU2020201550A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016015449A8 (pt) | 2020-06-09 |
| US20200031799A1 (en) | 2020-01-30 |
| AU2014373735A1 (en) | 2016-08-11 |
| MX2016008688A (es) | 2017-01-12 |
| EP3089746A4 (en) | 2017-08-30 |
| AU2014373735B2 (en) | 2020-03-12 |
| EP3089746A1 (en) | 2016-11-09 |
| EA032713B1 (ru) | 2019-07-31 |
| WO2015103317A1 (en) | 2015-07-09 |
| AU2020201550A1 (en) | 2020-03-19 |
| US20180170906A1 (en) | 2018-06-21 |
| KR20160106627A (ko) | 2016-09-12 |
| CN106061480B (zh) | 2020-02-28 |
| JP2017501205A (ja) | 2017-01-12 |
| EA201691354A1 (ru) | 2016-12-30 |
| JP6759100B2 (ja) | 2020-09-23 |
| CN106061480A (zh) | 2016-10-26 |
| US10266515B2 (en) | 2019-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014373735B2 (en) | Therapeutic inhibitory compounds | |
| US10221161B2 (en) | Inhibitors of plasma kallikrein | |
| CN104159896B (zh) | 用作激酶抑制剂的杂环取代的吡啶基化合物 | |
| US9855269B2 (en) | Aminoquinazoline and pyridopyrimidine derivatives | |
| CN104169275B (zh) | 用作激酶抑制剂的三唑取代的吡啶化合物 | |
| CN104254533B (zh) | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 | |
| KR100862879B1 (ko) | Ｈｉｖ 인테그라제의 ｎ-치환된 하이드록시피리미디논 카복스아미드 억제제 | |
| US9776995B2 (en) | Bicyclic sulfonamide compounds as sodium channel inhibitors | |
| RU2685234C1 (ru) | Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf | |
| JP7692353B2 (ja) | マトリプターゼ２阻害剤及びその使用 | |
| AU2018361249B2 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| TW200306180A (en) | New compounds | |
| KR20140020972A (ko) | 티아졸로피리미딘 화합물 | |
| CA3112735A1 (en) | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) | |
| TW202016090A (zh) | 經烷氧基取代之吡啶基衍生物 | |
| AU2023276708A1 (en) | Indolizine derivatives for treating trpm3-mediated disorders | |
| WO2025059562A1 (en) | Substituted aminopyridine compounds and methods of treating disease using same | |
| EP4499636A2 (en) | Pyrazolo[1,5-a]pyridine derivatives for treating trpm3-mediated disorders | |
| US11242333B2 (en) | Inhibitors of plasma kallikrein | |
| HK1230502A1 (en) | Therapeutic inhibitory compounds | |
| HK1230502B (en) | Therapeutic inhibitory compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20191230 |
|
| FZDE | Discontinued |
Effective date: 20230124 |